Background: Burrowing is a rodent behavior validated as a robust and reproducible outcome measure to infer the global effect of pain in several inflammatory pain models. However, less is known about the effect of analgesics on burrowing in neuropathic pain models and no studies have determined burrowing performance in models of diabetes-associated neuropathic pain. Objective: To compare the sensitivity of the burrowing assay in different neuropathic pain models: mononeuropathic pain and diabetic polyneuropathy. Methods: Burrowing performance was determined by the amount of substrate left in a hollow tube by rats with chronic constriction injury (CCI). In addition, burrowing performance, locomotion and pain development was assessed in the Zucker diabetic fatty (ZDF) rat model, resembling type-2 diabetes. Efficacy of clinically-active reference drugs (opioids, gabapentin and/or pregabalin) were investigated in these models. Burrowing behavior was additionally assessed in a second model, induced by streptozotocin (STZ) treatment, resembling type-1 diabetes. Results: In the CCI model, moderate but consistent burrowing deficits were observed that persisted over a period of ≥20 days. Systemic administration of morphine, pregabalin and gabapentin reversed this deficit. In contrast, none of the reference drugs improved marked burrowing deficits detected in ZDF rats, and pregabalin did not reverse severe burrowing deficits observed in STZ rats. Conclusions: Burrowing performance cannot necessarily be used as pain-related readout across pain models and largely depends on the model used, at least in models of neuropathy. Specifically, analgesic drug effects might be masked by general diabetes-associated alteration of the animals' well-being, resulting in false negative outcomes.
Introduction
Treatment options for neuropathic pain are characterized by limited efficacy and a narrow therapeutic window [1] [2] [3] . Thus, neuropathic pain remains an area of considerable unmet clinical need. Despite this, drug development activity in the pain field in general, and for neuropathic pain specifically, has considerably been downscaled in the past decade [3] . Inadequacy in the prediction of clinical efficacy from preclinical pain research is a major impediment to the development of new analgesic drugs and a potential major reason for this decline [4] [5] [6] . Consequently, the predictive value of preclinical models, especially pain readouts, has been questioned [4] [5] [6] . Rodent models of individual chronic pain conditions are crucial to improving our collective understanding of specific pathophysiological mechanisms and for screening new molecules as potential analgesic or adjuvant agents [7] . However, in preclinical pain research, an over-reliance on outcome measures utilizing withdrawal reflexes to sensory stimuli, typically evoked by mechanical or thermal stimuli, is a major challenge to predictive quality. Specifically, as these behavioral assessments rely on spinal and bulbospinal pathways and cannot account for the global impact of pain [8, 9] .
Furthermore, pain, is a subjective phenomenon that is inferred based upon behavioral responses in rodents, whereas in humans pain severity ratings are self-reported, encompassing intensity of the nociceptive stimulus and its resultant affective/emotional response [10] . Ethological approaches to preclinical pain research therefore aim to improve predictive validity by exploiting innate rodent behaviors that reflect the multi-dimensional nature of the pain experience. This approach enables the assessment of more complex behaviors involving supra-spinal pathways and examination of the global impact of preclinical pain models. Additionally, as pharmacological intervention aims to reinstate the suppressed innate behavior rather than diminishing an enhanced reflex response, doses that can impair motor function are prevented from becoming false positives [11, 12] .
Among these ethologically-relevant behaviors is burrowing, a behavior that is spontaneously expressed in rodents [13] . Pain-depressed burrowing performance has been reported in several rodent models of pain and can be normalized by clinically-active analgesics [8, 9, 11, 12, [14] [15] [16] [17] [18] , suggesting a degree of predictive validity for this outcome measure. Using a prospective multicenter design, we recently investigated and confirmed the reliability of pain-depressed burrowing performance as a novel pain-related outcome measure in rats with complete Freund adjuvant (CFA)-induced inflammatory pain [9] . However, only a limited number of studies have employed burrowing performance as an outcome measure for the assessment of neuropathic pain in general [10, 14, 17, 19] , and there are no studies that have investigated whether changes in burrowing behavior are related to neuropathic pain associated with diabetes. Here, we address this shortcoming by evaluating and comparing burrowing performance in rats following chronic constriction injury (CCI), a model associated with mononeuropathic pain, and two models of diabetes-associated polyneuropathic pain: streptozotocin (STZ)-induced polyneuropathy and polyneuropathy in the Zucker diabetic fatty (ZDF) rat model, resembling type-1 and type-2 diabetes, respectively. In addition, we determined the efficacy of different clinically-relevant and archetypal analgesics in these models.
Materials and methods

Animals
All animal experiments were authorized by the Local Animal Care and Use Committee and carried out according to the local animal care guidelines, Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) regulations, and the USDA Animal Welfare Act. For CCI experiments carried out at Boehringer Ingelheim, male Wistar Han rats (200-220 g; Charles River Laboratories, Sultzfeld, Germany) were used, and for experiments carried out at Grünenthal, male Sprague Dawley rats (180-200 g; Janvier Laboratories, Le Genest St Isle, France) were used. Animals were maintained on a 12 h light-dark cycle (lights on 06:00 [Grünenthal] or 07:00 [Boehringer Ingelheim]), with food (standard chow) and water available ad libitum, except during testing. Wistar rats and Sprague Dawley rats were housed in groups of 4 with environmental enrichment provided. Animal housing rooms were temperature (22 ± 2°C) and humidity (35-70%) controlled. Additionally, all experiments were in accordance to the recommendations set out by the International Association for the Study of Pain [20] and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines [21] .
STZ rat experiments were carried out at Grünenthal using Sprague Dawley rats, and ZDF rat experiments were carried out at Boehringer Ingelheim using ZDF (fa/fa) obese rats and Zucker lean (ZL; fa/+) control rats (Charles River, Germany), as previously described [22] . ZDF and ZL rats were fed a high fat diet (Provimi Kliba, Gossau, Switzerland) and housed in pairs in individually-ventilated cages. Blood glucose levels were monitored using a strip tester (One Touch; Lifescan, Johnson and Johnson, Canada).
Burrowing training: CCI experiments
Burrowing experiments performed at Boehringer Ingelheim (CCI, ZDF) followed a previously-documented protocol [8, 9, 11, 12, 18] . In short: For burrowing training of Wistar Han and ZDF rats, steel tubes (32 cm in length x 10 cm in diameter, manufactured in-house) were filled with 2.5 kg of quartz sand and placed in Plexiglas cages (600 × 340 × 200 mm). The open-end of the tube was elevated 6 cm from the floor of the cage. Training for each experiment was carried in 2 phases: social facilitation (SF) and individual training (IT). For SF rats were placed in pairs in a cage containing the sand-filled steel tube for 2 h on 2 consecutive days. The amount of sand burrowed by each pair was measured and if a pair burrowed < 1.5 kg of sand one of the pair was swapped with a rat from a pair that had burrowed > 1.5 kg for the second SF day. After SF there were three IT days, where rats were placed alone in the burrowing set-up for 30 min per day and the average amount burrowed over 3 days was calculated to attain a baseline burrowing performance value. Before model induction, animals were firstly randomly assigned to sham or CCI groups. To ensure that each group had a comparable baseline burrowing performance, some animals were re-grouped. The experimenter was blinded to the animal identity during this process. Following SF and IT, induction was carried out, as outlined below.
Burrowing experiments performed at Grünenthal (CCI and STZ) were conducted using an analogous protocol and comparable burrowing tubes to those outlined above and previously described [9, 12, 18] . In short, burrowing tubes are hollow plastic tubes (32 cm long × 10 cm diameter), standing on two plastic legs (60 mm high) situated on the open end of the tube (manufactured in-house). The tube was filled with 2.5 kg of pea shingle gravel with a diameter of 2-4 mm (ORBIT GmbH, Usingen, Germany). Specifically, all rats received 4 training sessions prior to the burrowing performance test. For training, rats were placed in cages with empty burrowing tubes (60 min on Day 1). On Days 2-4, animals spent 30 min in an empty cage, after which the gravel-filled tube was introduced for a 60-min session. Rats were placed into cages in pairs for training sessions (SF) on Days 1 and 2 and on their own for training sessions on Days 3 and 4 (IT). Baseline burrowing performance was tested on Day 5, after which animals were assigned to groups based on their burrowing performance. Animals burrowing < 500 g in total were excluded from the experiment (< 10%). Burrowing performance was re-assessed between 4-25 days after CCI surgery and 21 days after STZ injections.
Surgical procedure for chronic constriction injury
CCI was performed under 1-2% isoflurane anesthesia based on the original description by Bennett and Xie [23] as reported previously [24] . Briefly, the left sciatic nerve was exposed after the incision of skin and blunt separation of the muscle. The sciatic nerve was freed of the adhering tissue for about 7 mm and four ligatures (Catgut Chrom USP 4/0, metric 2; SMI, Belgium) were made loosely with a 1.0-1.5 mm interval between each. Great care was taken to tie the ligatures so that the diameter of the nerve was just barely constricted. Sham operations were identical, except that the nerve was not ligated. To confirm a neuropathic pain-like phenotype all CCI and Sham animals were tested for cold allodynia at Grünenthal one week after surgery on a metal plate (24 × 39.5 cm) cooled by a water bath to a constant temperature of 4°C. Animals are observed for 2 minutes and the number of brisk withdrawal reactions is counted. CCI Animals that did not develop cold allodynia were excluded from the study (< 5%).
Experimental outline of ZDF rat study and behavioral assessment
Sixteen ZDF rats and 16 ZL rats were obtained at 6 weeks of age, of which two ZDF rats and one ZL had to be euthanized due to a health condition in the course of the study. To monitor the development of hyperglycemia, blood glucose levels were monitored using a strip tester (One Touch; Lifescan, Johnson and Johnson, Canada) on a weekly basis until 13 weeks of age. Since blood glucose levels were relatively stable, they were thereafter only checked every 2-3 weeks until the end of study. In addition, body weight was monitored at the same time-points. Once blood glucose levels were maintained > 250 mg/dL, ZDF rats were deemed to be hyperglycemic. Burrowing training started at 7 weeks of age and the animals were re-baselined at 15 weeks of age, shortly before testing of analgesic drugs. In addition, spontaneous locomotor activity was measured for 30 min with an automated monitoring system (TruScan Activity Monitor version 2.0, Coulbourn Instruments, Allentown, PA, USA) at age 7, 14 and 31 weeks, as previously described [11, 25] . The parameters measured by the system were: ambulatory horizontal distance moved (cm), rearing frequency and rearing time (s). To monitor the development of mechanical sensitivity, paw withdrawal thresholds (PWT, g) were determined using a Randall Selitto analgesiometer and von Frey filaments, also as previously described [22, 26] . In short: Mechanical sensitivity to tactile stimuli was measured at the plantar area of left hind paw with a set of calibrated fiberglass von Frey filaments (Marstock nervtest, Marburg, Germany) using the up-down method [27, 28] . Rats were placed on a wire mesh floor in plexiglass boxes which allowed a full access to the plantar areas of paws. The animals were allowed to habituate for at least 10 min until exploratory behavior ceased. Every stimulus was applied until a withdrawal reaction occurred with a cut off duration of 8 s. The set of individual filaments delivered logarithmic incremental forces and consisted of the following weights: 1.4; 2.0; 2.8; 4.0; 5.7; 8.0; 11.3; 16.0; 22.6 g. The individual stimuli were applied with at least 5 min time intervals in each individual rat. Mechanical sensitivity to pressure stimuli was measured by Randall Selitto test [29] with an Ugo Basile Analgesimeter (Ugo Basille SRL, Comerio, Italy). A linearly increasing mechanical force (cut off 250 g) was applied to the mid-plantar left hind paw until a withdrawal reaction occurred. The corresponding mechanical weight was taken as withdrawal threshold in grams. Three mechanical stimuli were delivered for each individual rat with at least 5 min intervals and an average was obtained to estimate an individual latency value.
Burrowing experiments (i.e. testing of analgesic drugs), commenced once the ZDF rats maintained hyperglycemia and mechanical hypersensitivity, i.e. post 15 weeks of age. Gabapentin experiments were performed at 16, 21, 37 weeks of age, pregabalin at age 23 and 33 weeks, tramadol at 31 weeks, and morphine at 34 weeks of age). body weight (at time of STZ/citrate treatment). Diabetes was confirmed 1 week later by measurement of tail vein blood glucose level with a Haemoglukotest 20R -800R (Boehringer Mannheim GmbH, Germany) and a reflectance colorimeter (Hestia Pharma GmbH, FRG). Rats with a final blood glucose level of at least 27 mM were considered diabetic and thus included in the study. Control animals were treated with the (citrate) vehicle solution. Mechanical hypersensitivity was confirmed by a paw pressure test previously described [23] using an analgesiometer (as outlined in Section 2.4). Of note, in the STZ model the health status of animals is affected resulting in a loss of body weight which stabilizes during the first two weeks after STZ injection. To prevent decreasing health status to confound behavioral readouts, burrowing performance of vehicle-treated and STZ rats with confirmed hyperglycemia and mechanical hypersensitivity was assessed 3 weeks post STZ treatment.
Experimental outline of STZ rat studies
Drugs and drug administration
Unless otherwise stated, all chemicals and drugs were purchased from Sigma-Aldrich (Taufkirchen, Germany). We chose to conduct pharmacological studies using drugs prescribed clinically for the treatment of neuropathic pain associated with both nerve injury and diabetic neuropathy: opioids and gabapentinoids [30] . The drugs used were morphine (Grünenthal: Macfarlan Smith Ltd, Edinburgh, UK; Boehringer Ingelheim: Caelo, Germany), tramadol (Grünenthal and Boehringer Ingelheim: Sigma-Aldrich, Taufkirchen, Germany), gabapentin (Grünenthal: Tocris Bioscience, Bristol, UK, Boehringer Ingelheim: Tokyo Chemical Industry, Japan) and pregabalin (Grünenthal and Boehringer Ingelheim: 3B Pharmachem, China). All drugs were dissolved in physiological saline (0.9%), except pregabalin and tramadol, which were both stably suspended in 0.5% (w/v) natrosol and 0.1% (v/v) tween-80 (9:1 ratio). Drug doses were chosen based on inhouse experience and previous burrowing literature [8, 11, 12, 14, 18, 31] . Doses used in the studies ranged from 0.1-6 mg/kg for morphine, 3.16-61.6 mg/kg for pregabalin, 25-60 mg/kg for gabapentin, and 10-100 mg/kg for tramadol. Further details regarding drug doses, route of administration, pre-treatment times and details on animal numbers per group, are shown in Table 1 .
Statistical analysis
Statistical analyses were performed in GraphPad Prism version 6.0 (San Diego, CA, USA). A P value of < 0.05 was considered statistically significant for all data analyzed. CCI time-course data were analyzed using a two-way repeated measured (RM) ANOVA with a Bonferroni correction for multiple comparisons. Data from pharmacology studies were analyzed using a one-way ANOVA with a Dunnett's correction for multiple comparisons. A Dunnett's correction was chosen for pharmacology studies, as the drug treatment groups were compared to a single vehicle control group. Area under the curve (AUC) data were calculated using an unpaired, two-sided Student's t-test. Burrowing baseline data of ZDF and ZL rats, PWT data and locomotor activity data were calculated using an unpaired, two-sided Student's t-test. Data from burrowing pharmacology studies were analyzed using a two-way ANOVA with a Dunnett's correction for multiple comparisons, except when a main effect of drug was seen, i.e. tramadol study, where a Bonferroni post-hoc analysis was used to correct for multiple comparisons. Equally, STZ data were calculated using a two-way ANOVA with a Bonferroni correction for multiple comparisons. All data were tested for normality using a Shapiro-Wilk test.
Results
Evaluation of burrowing performance in rats with CCI and effect of analgesic drugs on CCI induced burrowing deficits
Over the 20-day time course, burrowing performance (sand as a substrate; Boehringer Ingelheim) in CCI-treated rats was lower than in Sham treated rats (F (1,24) = 7.754, p = 0.0103), and was confirmed by the significantly smaller AUC of CCI-treated rats compared with Sham treatment (Fig. 1A , right panel, p = 0.0145). Burrowing performance was stable over time in Sham treated rats, i.e. performance did not differ compared to baseline performance. In contrast, burrowing performance significantly declined in CCI-treated rats when compared to their pre-surgery baseline on day 17 and day 20 post surgery (Fig. 1A , left panel; p = 0.0033 and p = 0.0009, respectively). Additionally, CCI rats burrowed significantly less on day 8 compared to the respective Sham group (Fig. 1A , left panel; p = 0.376. CCI-induced burrowing deficits were even more pronounced in a study performed in parallel at Grünenthal, where gravel was used as a substrate. Following surgery, the overall burrowing performance of CCI-treated rats was significantly impaired compared to Sham-treated rats (F (1,14) = 47.68, p < 0.0001), confirmed by the significantly smaller AUC of CCI-treated rats compared with Sham treatment (Fig. 1B , right panel, p < 0.0001), and on each experimental day following surgery this difference was significant ( Fig. 1 B, left panel ; p = 0.0008 at day4, p < 0.0001 at day 7, p = 0.0005 at day 11, p = 0.0111 at day 15, p < 0.0001 at day 19, p = 0.097 at day 22 and p < 0.0001 day 25). In addition, burrowing performance significantly declined in CCI-treated rats when compared to their pre-surgery baseline on most days (Fig. 1B, left panel ; p = 0.0094 at Day4, p = 0.0160 at day 7, p = 0.0117 at day 11, p = 0.0453 at day 22 and p = 0.0136 at day 25). Individual burrowing performance was not correlated with the evoked cold allodynia response assessed 7 days after CCI surgery (Supplementary Fig. 1 ).
To determine if CCI-induced burrowing deficits are reversible by clinically-active analgesic drugs, we determined the effects of morphine, pregabalin and gabapentin on burrowing performance 11-28 days post-surgery (Fig. 2) . We chose gravel as a substrate as this provided the most consistent burrowing deficits in the CCI model (Fig. 1) . A significant reduction of burrowing performance was demonstrated in vehicle-treated CCI rats vs vehicle-treated Sham rats in all studies ( Fig. 2A-C; p < 0.001, p < 0.001, p = 0.0036, respectively) . Morphine (0.1 mg/kg) significantly reversed CCI-induced burrowing deficits when compared to vehicle-treated CCI rats (F (4,54) = 8.223; p = 0.0004), whereas higher doses of morphine only trended towards improvement, (Fig. 2 A ; p = 0.0670 and p = 0.0772 for 0.316 mg/kg and 1 mg/kg, respectively. Similarly, pregabalin normalized CCI-induced burrowing deficits significantly (F (4,54) = 11.13; p < 0.0001) at all doses tested (Fig. 1B ; p = 0.0025, p < 0.0001 and p < 0.0001 for 3.16 mg/kg, 10 mg/kg and 31.6 mg/kg, respectively), as did gabapentin (F (3,114) = 8.224; p < 0.0001) at both doses tested ( Fig. 1C ; p = 0.0265 and p = 0.0001 for 25 mg/kg and 50 mg/kg, respectively).
3.2. Characterization of hyperglycemia, pain sensitivity and spontaneous behaviors in ZDF rats ZDF rats developed hyperglycemia at 8 weeks of age which plateaued at 13 weeks age at around 500 mg/dL which was then maintained for the rest of the study (Fig. 3A) . Temporal changes in body weights of ZL and ZDF rats over the course of the study is given in Fig. 3B .
Mechanical sensitivity, as assessed using the Randall Selitto test (Fig. 4A, B ) and von Frey filaments (Fig. 4C, D) , was not different between ZDF rats and ZL rats aged 7 weeks (Fig. 4A , p = 0.1319 and Fig. 4C , p = 0.1473). In contrast, development of significant mechanical hypersensitivity was observed in ZDF rats compared to ZL rats aged 15 weeks (Fig. 4B , p < 0.0001 and Fig. 4D ; p = 0.0138).
At 7 weeks of age, ZDF rats burrowed slightly lower amounts of sand compared with ZL rats (Fig. 5A ; p = 0.0291). This burrowing deficit was even more pronounced when the performance was reassessed at 15 weeks of age ( Fig. 5B ; p < 0.0001). When correlating the rats' individual burrowing performance with the two evoked pain response measures (Randall Selitto test and von Frey filaments), assessed in close timely proximity, no significant correlation was found ( Supplementary  Fig. 2 ). In line with the burrowing deficit observed in ZDF rats, assessment of spontaneous locomotor activity at 7 and 15 weeks of age indicated that ZDF rats travelled significantly less distance and showed less rearing behavior than ZL rats (Supplementary Fig. 3 ). This deficit was maintained when spontaneous locomotor activity was reassessed at 31 weeks of age (data not shown).
Effect of analgesic drugs of burrowing performance in ZDF rats
Pharmacological burrowing experiments commenced once the ZDF rats developed hyperglycemia and once development of mechanical hypersensitivity was confirmed (i.e. post 15 weeks of age). A main effect of ZDF genotype on burrowing performance across all pharmacological experiments conducted (p < 0.0001 in all cases) was observed, indicating a significant burrowing performance deficit in ZDF rats compared with ZL rats (Fig. 6 ). Neither pregabalin (10 or 30 mg/kg p.o.) nor gabapentin (30 or 45 mg/kg i.p.) affected burrowing performance in ZDF rats nor in ZL rats (Fig. 6A, B) . Similarly, neither morphine (Fig. 6C) nor tramadol (Fig. 6D ) reversed burrowing deficits in ZDF rats at any dose tested. However, as the two-way ANOVA indicated a main effect of tramadol (F (3,112) = 15.58; p < 0.0001, Bonferroni post-hoc testing was used to determine differences of drug treatment vs vehicle-treated ZDF and ZL rats. In ZDF rats, an impaired burrowing performance at both tramadol doses (30 and 100 mg/kg) was observed (p < 0.0001 for both doses), whereas tramadol treatment had no significant effect on burrowing performance in ZL rats (p > 0.9999 and p = 0.3472 for 30 and 100 mg/kg).
Evaluation of burrowing performance in STZ treated rats and effect of analgesic drugs on STZ induced burrowing deficits
Since the pharmacological studies in ZDF rats showed that different clinically-used analgesic drugs were unable to reverse burrowing deficits in a rat model of type-2 diabetes, we then explored burrowing performance and efficacy of analgesic drugs in a second more commonly used model of painful diabetic polyneuropathy, the STZ model, which resembles type-1 diabetes.
STZ treatment resulted in a marked deficit in the amount of gravel burrowed 3 weeks post STZ administration ((F (1, 18) = 566.3, p < 0.0001, Fig. 7A; (F (1,17) = 167.7, p < 0.0001, Fig. 7B) ; burrowing behavior was essentially almost absent and indeed, several animals did not burrow at all. Burrowing deficits did not correlate with mechanical sensitivity assessed 3 weeks after STZ administration using the Randall Sellito test (Supplementary Fig. 4) . Pregabalin given at a dose of 10 mg/ kg i.p. (Fig. 7A ) or 31.6 mg/kg i.p. (Fig. 7B) failed to reinstate burrowing behavior in STZ-treated rats. We also dosed a group of STZ rats with pregabalin once daily for three consecutive days prior to examining burrowing behavior and again found burrowing performance was not reinstated (data not shown).
Discussion
Here we report burrowing deficits in three different rat models of neuropathic pain that differ in the degree of observed burrowing depression. Whereas moderate deficits were demonstrated in the CCI model severe reductions in burrowing performance were seen in STZ rats. In ZDF rats, slight differences in burrowing performance compared with ZL rats were detected at onset of diabetes, which became more prominent with diabetes chronicity. Importantly, the fact that . 3 . Mean blood glucose levels (A) and mean body weight (B) of ZDF and ZL rats over the course of the study. Blood glucose levels (A; mg/dL) of ZDF (dark gray) and ZL rats (light gray) over time. Starting at 7 weeks of age, blood glucose levels were monitored weekly until 11 weeks and thereafter every second week until end of the study. ZDF rats were deemed to be hyperglycemic once blood glucose levels of > 250 mg/dL were achieved (dotted line), which was already the case at 8 weeks of age. Blood glucose levels in ZDF rat plateaued around 500 mg/dL from 10 weeks of age. In contrast, ZL rats had constant blood glucose levels around 110 mg/dL. (B) Body weight (g) of ZDF (dark gray) and ZL rats (light gray) over time. Starting at 7 weeks of age, body weight was assessed in parallel with blood glucose assessment. ZDF rats showed a slightly higher body weight in the first age weeks compared with ZL rats and their body weight plateaued at 400 g at 19 weeks of age, the same time that ZL rats achieved the same body weight. However, body weight of ZL rats continued to increase and plateaued around 450 g. Data are expressed as means + SEM. SEM, standard error of the mean; ZDF, Zucker Diabetic Fatty; ZL, Lean Zucker Diabetic Fatty. Fig. 4 . Mechanical sensitivity of ZL and ZDF rats at 7 (A-B) and 15 (C-D) weeks of age. (A) At 7 weeks, mechanical sensitivity as assessed using the Randall Selitto test and the mechanical force in gram (g) that resulted in paw withdrawal did not differ between ZDF and ZL rats. In contrast, reassessment of mechanical sensitivity at 15 weeks indicated a significant reduction in mechanical force required to elicit the paw withdrawal reflex in ZDF rats (B). Similarly, mechanical sensitivity assessed using von Frey filaments indicated no significant difference in withdrawal thresholds between ZL and ZDF rat 7 weeks (C) but a significant difference at 15 weeks (D). Data are expressed as means + SEM. *p < 0.05, ****p < 0.0001. SEM, standard error of the mean; ZDF, Zucker Diabetic Fatty; ZL, Lean Zucker Diabetic Fatty.
clinically-active analgesic drugs normalized CCI-induced burrowing deficits but not the burrowing deficits associated with diabetes pathophysiology, has particular relevance for the use of the burrowing paradigm as an outcome measure to infer the global effect of pain on rodents. Although the burrowing paradigm has been considered as an important and possibly predictive outcome measure up to now, it cannot be applied in all preclinical models of pain.
Neuropathic pain has multiple aspects, including ongoing pain, spontaneous pain and stimulus hypersensitivity [32] , with the severity of each aspect varying from patient to patient. Ongoing and spontaneous pain are ubiquitous features of neuropathic pain and predict the severity of pain ratings more robustly than the presence of hypersensitivity [33] . Defining and characterizing a quantitative measure of ongoing and/or spontaneous pain in rodent models has proven challenging. The majority of published studies with rodent models use evoked endpoints to measure mechanical or thermal hypersensitivity [34] , largely overlooking ongoing or spontaneous pain -arguably the most fundamental clinical aspects of neuropathic pain. Pain is a Fig. 5 . Total amount of sand burrowed by ZL rats and ZDF rats at 7 (A) and 15 (B) weeks of age. ZDF rats burrow significantly less sand compared with ZL rats at 7 weeks, an effect that was even more pronounced when burrowing performance was reassessed at 15 weeks. Data are expressed as means + SEM. *p < 0.05, ****p < 0.0001. SEM, standard error of the mean; ZDF, Zucker Diabetic Fatty; ZL, Lean Zucker Diabetic Fatty. Fig. 6 . The effect of pregabalin, gabapentin, morphine and tramadol on burrowing performance in ZDF and ZL rats (A-D) . In all studies, ZDF rats (light gray) displaced significantly less sand from the burrowing tubes compared with ZL rats (dark gray). Pregabalin (A), gabapentin (B) and morphine (C) had no effect of burrowing performance in ZDF or ZL rats. In contrast, tramadol further reduced burrowing performance in ZDF rats but not in ZL rats at doses of both 30 and 100 mg/ kg when compared with vehicle-treated ZDF rats (D). In ZL rats, a similar trend in reduction of burrowing performance was seen that was not significant. Data are expressed as means + SEM. ****p < 0.0001, main effect of group (ZDF vs ZL); ####p < 0.0001 vs respective ZL group. SEM, standard error of the mean; SEM, standard error of the mean; ZDF, Zucker Diabetic Fatty; ZL, Lean Zucker Diabetic Fatty. subjective experience when assessed clinically, rendering it a difficult aspect to define in rodent models. However, a variety of assays have emerged in an attempt to determine ongoing pain and analgesic action, such as anxiety-like behavior [19] , conditioned place preference [35] [36] [37] locomotor activity [38] [39] [40] [41] , as well as depressive-like behavior [42, 43] and cognitive impairments [44, 45] . The advantage of measuring a spontaneously-expressed behavior like burrowing, as opposed to a reflex withdrawal, is that such behaviors are more ethologicallyrelevant to rodents [14] , and therefore offer better face validity than currently-used measures of hypersensitivity. Moreover, reflex withdrawal assays may not be measuring the ongoing or spontaneous aspects of pain [34, 46] , which are universal to people suffering from neuropathic pain [32] and are thus important aspects to consider preclinically.
Burrowing is a behavior conserved across rodent species [47] and a plethora of studies consistently suggest depression of burrowing performance in various pain states. Specifically, deficits in burrowing behavior have reliably been demonstrated in rat models of CFA inflammatory pain by us and others [8, 9, 12, 14, 18] and the early phase of the monosodium iodoacetate model of osteoarthritis [11] . Although burrowing is affected by many types of lesion, in pain models burrowing deficits are reversed by analgesics, suggesting a pain-specific component [8, 9, 11, 12, 14, [16] [17] [18] . In agreement with data from inflammatory pain conditions, a burrowing deficit has also been demonstrated in several models of neuropathic pain, specifically the tibial nerve transection (TNT), spinal nerve transection (SNT), partial sciatic nerve ligation (PSNL),spared nerve injury (SNI) model [14, 17] , which can be reinstated by analgesic drugs [14, 17] . Consistent with this literature, our study demonstrates moderate but consistent burrowing deficits in the CCI model starting 4-8 days post CCI surgery [10] that persisted until end of the studies (20 and 25 days). These deficits proved to be unrelated to cold allodynia assessed 7 days after CCI surgery. However, until now, there had been no pharmacological validation of this model. In this study, pregabalin and gabapentin fully normalized CCI-depressed burrowing performance at 3-30 mg/kg and 25-50 mg/kg, respectively. Similarly, Andrews et al. [14] reported that 30 and 100 mg/kg of gabapentin significantly reversed burrowing deficits seen in TNT rats, while only the 100 mg/kg dose significantly reversed deficits in PSNL rats. Equally, pregabalin reversed the burrowing deficit evident in SNI rats at a dose of 10 mg/kg [17] . In our study, as expected, CCI-induced burrowing deficits could also be reinstated by morphine, an opioid with clinically efficacy in neuropathic pain conditions, at a dose of 0.1 mg/kg, whereas doses of 0.316 and 1 mg/kg of morphine only trended towards improvement. Previous studies by us and other have shown that high doses of morphine can negatively impact spontaneous locomotion and burrowing performance in rats due to sedative side effects [8, 11, 40] , which is why the highest dose selected here was 1 mg/kg. In our hands, the burrowing deficit was reversed by the lowest (0.1 mg/kg) but not the higher (0.316 and 1 mg/kg) doses. It is possible that a mild sedative effect blunted any analgesic improvement of burrowing performance at these higher doses; indeed, morphine at 1 mg/kg (s.c.) is sufficient to reduce locomotor activity [36] . False positives may be detected in pain assays based on paw withdrawal when opioids are tested at doses causing impaired motor functioning and tone, which could inhibit withdrawal reflexes and thus be perceived as analgesic efficacy. However, studying the improvement of innate behaviors suppressed by pain bears the advantage that compounds which impair motor function should not appear as false positives [8, 14] .
To the best of our knowledge, there are currently no published studies determining burrowing performance in rodent models of painful diabetic polyneuropathy. To further characterize neuropathic pain models in the burrowing paradigm, we investigated whether deficits occurred in ZDF rats. ZDF rats are a genetic model of impaired glucose tolerance and type-2 diabetes [48] . Zucker rats that are leptin receptordeficient (fa/fa) develop obesity and insulin resistance at a young age and progressively develop hyperglycemia [49] , while Zucker fa/+ rats remain lean and normoglycemic (ZL). A lower burrowing performance was observed in ZDF vs ZL rats as early as 7 weeks of age, at which time hyperglycemia was evident but sensitivity to both mechanical pressure and tactile stimuli was absent. This difference in burrowing was even more pronounced with increasing age; burrowing performance in ZDF rats aged 15 weeks and older was lower compared with ZL rats, i.e. when diabetes became more chronic and hypersensitivity was evident. The increased difference in burrowing performance was largely driven by ZL rats, which showed a higher burrowing performance at 15 vs 7 weeks of age as a result of increased age and weight [9] , whereas burrowing performance of ZDF rats remained unchanged at age 15 weeks when compared to age 7 weeks. Mechanical hyperalgesia has previously been reported in ZDF rats [50, 51] and was also present in this study when mechanical hypersensitivity was assessed at 15 weeks of age. As mechanical hypersensitivity was absent at 8 weeks of age (the onset of hyperglycemia), our data may suggest that only at the chronic stage of diabetes (∼15 weeks) does the nerve damage manifest as mechanical hypersensitivity. There was no significant correlation between burrowing performance and evoked pain response measures. In addition, spontaneous locomotor activity of ZDF rats was reduced compared with ZL rats at onset of hyperglycemia, a finding became even more pronounced with increased age and duration of diabetes.
In contrast to our expectation, the burrowing deficits observed in ZDF rats were not reversible by different clinically-active drugs, i.e. pregabalin, gabapentin, morphine and tramadol, tested at doses that have previously been shown to be active in both burrowing assays and reflex-based outcome measures in multiple pain models. Even three days subacute twice daily dosing of 30 or 45 mg/kg of gabapentin did not improve burrowing performance of ZDF rats (data not shown). To A-B) . The amount of gravel burrowed by STZ rats was markedly reduced in comparison to citrate control animals (A, B). Administration of 10 mg/kg (A) or 31.6 mg/kg (B) pregabalin had no effect on burrowing performance in STZ rats. ****p < 0.0001 vs respective citrate control group. Data are expressed as means + SEM. SEM, standard error of the mean; STZ, streptozotocin.
further characterize the burrowing paradigm in diabetic neuropathy models and to determine if this observation in ZDF could potentially be generalized for other diabetic neuropathy models, we subsequently investigated burrowing performance in STZ-treated rats. Currently, preclinical evaluation of the analgesic efficacy of novel compounds for diabetic polyneuropathy is mostly based on the STZ model, in which STZ is toxic to insulin-producing pancreatic beta cells and thus causes a rapid induction of hyperglycemia [52] .
A marked depression of burrowing behavior was observed in these rats, which was more pronounced than in the CCI model and at best qualitatively similar to that seen in ZDF rats. Burrowing deficits did not correlate with mechanical sensitivity assessed 3 weeks after STZ administration. As with ZDF rats, pregabalin did not reverse burrowing deficits in STZ treated rats. Equally, three days sub-acute twice daily dosing of 10 and 30 mg/kg, did not improve burrowing performance of STZ rats compared with vehicle treatment (data not shown). One suggestion for the lack of burrowing performance restoration in both ZDF and STZ may be that diabetes-associated neuropathic pain is less sensitive to reversal by analgesic drugs compared with pain models of mononeuropathy. This appears somewhat unlikely, given that the efficacy of analgesic drugs usually does not differ between diabetic and mononeuropathic pain models, at least when using classical paw withdrawal-based behavioral paradigms [53] . However, future studies to directly compare and correlate efficacy of different analgesic drugs on various evoked and non-evoked outcome measures across different models of neuropathic pain are warranted to address this posibility.
Alternatively, the effect of analgesic drugs might be masked by a general diabetes-associated alteration of the animals' well-being. Indeed, burrowing deficits themselves have been suggested to reflect a reduction in animal well-being [13, 54] , given that several experimental manipulations that may not necessarily be pain-associated, including hippocampal cytotoxic lesions, hippocampal scrapie infection and medial prefrontal cortex lesions, impair burrowing performance [55] [56] [57] [58] . Reduced burrowing performance has also been observed in an Alzheimer's disease model [59, 60] . Furthermore, a sickness behavior response following immune system activation, e.g. after bacterial or viral infection, is normally characterized by changes in motivation to engage in certain activities including burrowing behavior [61] [62] [63] . In such settings, burrowing behavior can be restored by treatment with non-steroidal anti-inflammatory drugs [64, 65] . Therefore, it is at least conceivable that the burrowing deficits demonstrated here in the two diabetes models are reflecting sickness behavior, sickness-associated changes in motivation, i.e. anhedonia, or other secondary complications associated with the diabetic state. These factors, which may possibly be more severe than the neuropathic pain state, might drive the deficit in burrowing behavior and thus mask the efficacy of analgesic drugs. This would also explain why paw withdrawal-based behavioral assays are still capable of detecting drug effects, as the animal's response to the stimulus is forced/reflexive. Looking forward, burrowing may be a useful tool for assessing whether drugs designed to restore normoglycemia, or target the etiological disease mechanisms, improve the global health and well-being state in rodent models of diabetes.
Conclusions
We show burrowing deficits in three different models of neuropathic pain, of which only those elicited by mononeuropathic pain (CCI), and not those associated with diabetes, were reversible by clinically-active analgesics. The data indicate that burrowing performance may be limited in its use as a pain-related readout in diabetic polyneuropathy pain models, and that its utility to assess a pain component largely depends on additional factors that are not necessarily pain related. In the context of the diabetes models employed here, the effect of analgesic drugs might be masked by general diabetes-associated alteration of the animals' well-being; i.e. well-being is compromised to an extent that any analgesic efficacy may be missed due to the overall illness of the animals, possibly resulting in false negative outcomes. 
